PositiveID's ExcitePCR Subsidiary CEO to Speak on National Academies of Science, Engineering, and Medicine Panel Today
September 18 2017 - 10:50AM
InvestorsHub NewsWire
PositiveID’s ExcitePCR Subsidiary CEO to Speak
on National Academies of Science, Engineering, and Medicine Panel
Today
Three-person BioWatch panel on current and
future advancements in pathogen detection systems will be held at
3:30 pm in Washington, D.C.
DELRAY BEACH, FL --
September 18, 2017 -- InvestorsHub NewsWire -- PositiveID
Corporation’s (OTCQB:
PSID) ExcitePCR
subsidiary’s
President, CEO, and
Founder Lyle L. Probst, will be featured today on a BioWatch
panel discussion
about current and future advancements in pathogen detection systems
hosted by the National Academies of Science,
Engineering and Medicine (NAS) at 500 Fifth Street NW in
Washington, D.C.
The three-member
panel discussion, titled “Novel Technologies to Expand
Capabilities,” is part of a two-day NAS public workshop on
Strategies for Effective
Biological Detection Systems, and will be held from
3:30-4:30 p.m. (ET) at the Fred Kavli Auditorium at NAS
headquarters.
For over 17 years,
Probst has been on the forefront of government- and business-led
efforts to improve the ability to quickly and accurately identify
harmful biological agents, including his roles as a Biomedical
Scientist/Project Manager at Lawrence Livermore National
Laboratory, as Vice President of Operations & Business
Development for Microfluidic Systems, as President of PositiveID,
and most recently, as CEO of ExcitePCR.
ExcitePCR is
currently developing the FireflyDX™ family of portable pathogen
detection systems, which includes the FireflyDX-Portable™ and the
FireflyDX-Handheld™. The FireflyDX-Portable is a rechargeable,
bookbag-sized, realtime pathogen detection system designed to
enable first responders, medical professionals and food safety
officials to accurately obtain on-site results anywhere in the
world in less than 30 minutes, including sample preparation time.
ExcitePCR expects the FireflyDX-Portable will be commercially
available in summer 2018. The FireflyDX-Handheld, a miniaturized
version of the FireflyDX-Portable, is designed to fit in the palm
of the hand and provide lab-quality sample to detection in less
than 30 minutes at the point of need/point of care.
For more
information about NAS or its BioWatch panel discussion, please
contact the National Academies of Science, Engineering and Medicine
at 202-334-2000.
About
PositiveID Corporation
PositiveID
Corporation is a holding company focused on life sciences,
diagnostics, mobile laboratories, and medical devices.
PositiveID’s ExcitePCR
subsidiary is
developing the FireflyDX family of pathogen detection systems,
portable devices offering rapid sample-to-result detection in less
than 30 minutes using real-time polymerase chain reaction
chemistry. PositiveID’s E-N-G Mobile
Systems™
subsidiary is a leader in the mobile technology vehicle market,
with a focus on the laboratory market and homeland security.
PositiveID’s Thermomedics™
subsidiary markets
the FDA-cleared Caregiver® non-contact thermometer for clinical
use. For more information on PositiveID, please visit
http://www.psidcorp.com,
or connect with PositiveID on Twitter,
Facebook
or LinkedIn.
On August 24, 2017,
PositiveID Corporation and its wholly-owned subsidiary PositiveID
Diagnostics, Inc. (collectively, the “Seller”), entered into
an Asset Purchase Agreement (“APA”) with ExcitePCR Corporation.
Pursuant to the APA, at closing, the Seller will sell and deliver
to ExcitePCR all assets used in connection with the operation of
the FireflyDX technology. For more information on the APA, please
read PositiveID’s Form 8-K filed on August 28, 2017, which can be
found here.
Statements about PositiveID's future
expectations, including the likelihood that ExcitePCR is currently
developing the FireflyDX family of portable pathogen detection
systems; the likelihood that the FireflyDX-Portable is a
rechargeable, bookbag-sized, realtime pathogen detection system
designed to enable first responders, medical professionals and food
safety officials to accurately obtain on-site results anywhere in
the world in less than 30 minutes, including sample preparation
time; the likelihood that the FireflyDX-Portable will be
commercially available in summer 2018; the likelihood that the
FireflyDX-Handheld, a miniaturized version of the
FireflyDX-Portable, is designed to fit in the palm of the hand and
provide lab-quality sample to detection in less than 30 minutes at
the point of need/point of care; the likelihood that pursuant to
the APA, at closing, the Seller will sell and deliver to ExcitePCR
all assets used in connection with the operation of the FireflyDX
technology; constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and PositiveID's actual results could differ
materially from expected results. These risks and uncertainties
include, without limitation, ExcitePCR’s ability to complete a
financing of at least $3 million; PositiveID’s and ExcitePCR’s
ability to close the asset purchase agreement among PositiveID,
PositiveID Diagnostics, and ExcitePCR; PositiveID’s ability to
attract new customers and partners; PositiveID’s ability to raise
capital; ExcitePCR’s ability to complete the development and
commercialization of the FireflyDX-Portable and FireflyDX-Handheld;
as well as other risks. Additional information about these and
other factors that could affect the Company's business is set forth
in the Company's various filings with the Securities and Exchange
Commission, including those set forth in the Company's 10-K filed
on March 31, 2017, and 10-Qs filed on August 14, 2017, May 15,
2017, and November 18, 2016, under the caption "Risk Factors." The
Company undertakes no obligation to update or release any revisions
to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by
law.
Contacts:
PositiveID
Corporation
Allison
Tomek
(561)
805-8044
atomek@psidcorp.com